Re-wiring the circuit: Mitochondria as a pharmacological target in liver disease

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5448-5465

  Diogo, C V ^a   Grattagliano, I ^b   Oliveira, P J ^a   Bonfrate, L ^b   Portincasa, P ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Alcohol; Cholestasis; Drug induced liver injury; Glutathione; Ischemia reperfusion; Liver diseases; Medicinal chemistry; Mitochondria; Oxidative stress; Pharmacology; Reactive oxygen species

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CARVEDILOL; DEOXYCHOLIC ACID; DICLOFENAC; GLUTATHIONE DERIVATIVE; GLYCOCHENODEOXYCHOLIC ACID; GLYCODEOXYCHOLIC ACID; GLYCOLITHOCHOLIC ACID; HEMOJUVELIN; IDEBENONE; LITHOCHOLIC ACID; MINOCYCLINE; PARACETAMOL; PEROXIREDOXIN 6; REACTIVE OXYGEN METABOLITE; SILIBININ; TAUROCHENODEOXYCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; UBIDECARENONE; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; AORTA ANEURYSM; ARTICLE; CHOLESTASIS; CHOLESTEROL STONE; CHRONIC DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; METASTASIS; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SCLERODERMA; WILSON DISEASE;

ANIMALS; ANTIOXIDANTS; DRUG DELIVERY SYSTEMS; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; HUMANS; LIVER DISEASES; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 82255173714     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194432     Document Type: Article

References (219)

1. Szewczyk, A.; Wojtczak, L. Mitochondria as a pharmacological target. Pharmacol. Rev., 2002, 54, (1), 101-127 (Pubitemid 34211027)
2. Pereira, C. V.; Moreira, A. C.; Pereira, S. P.; Machado, N. G.; Carvalho, F. S.; Sardao, V. A.; Oliveira, P. J. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf, 2009, 4, (1), 34-54
3. Benard, G.; Rossignol, R. Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid. Redox. Signal., 2008, 10, (8), 1313-1342
4. Begriche, K.; Massart, J.; Robin, M. A.; Borgne-Sanchez, A.; Fromenty, B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol., 2010, 54, (4), 773-794
5. Labbe, G.; Pessayre, D.; Fromenty, B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol., 2008, 22, (4), 335-353
6. Daiber, A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim. Biophys. Acta, 2010, 1797, (6-7), 897-906
7. Smith, R. A.; Porteous, C. M.; Coulter, C. V.; Murphy, M. P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem., 1999, 263, (3), 709-716 (Pubitemid 29361943)
8. Rigoulet, M.; Yoboue, E. D.; Devin, A. Mitochondrial ROS generation and its regulation: mechanisms involved in H (2) O (2) signaling. Antioxid. Redox. Signal., 2010, 14, (3), 459-468
9. Muriel, P. Role of free radicals in liver diseases. Hepatol Int, 2009
10. Lee, S. J.; Jin, Y.; Yoon, H. Y.; Choi, B. O.; Kim, H. C.; Oh, Y. K.; Kim, H. S.; Kim, W. K. Ciclopirox protects mitochondria from hydrogen peroxide toxicity. B r. J. Pharmacol., 2005, 145, (4), 469-476 (Pubitemid 40966276)
11. Kowaltowski, A. J.; de Souza-Pinto, N. C.; Castilho, R. F.; Vercesi, A. E. Mitochondria and reactive oxygen species. Free Radic. Biol. Med., 2009, 47, (4), 333-343
12. Kowaltowski, A. J.; Vercesi, A. E. Mitochondrial damage induced by conditions of oxidative stress. Free Radic. Biol. Med., 1999, 26, (3-4), 463-471 (Pubitemid 29013479)
13. 2+ ions. A proposed model for phosphate-stimulated lipid peroxidation. J. Biol. Chem., 1996, 271, (6), 2929-2934
14. 2+: effect of coenzyme Q redox state. Free Radic. Biol. Med., 1995, 18, (1), 55-59
15. Cadenas, E.; Davies, K. J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med., 2000, 29, (3-4), 222-230
16. Kim, J. S.; He, L.; Lemasters, J. J. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem. Biophys. Res. Commun., 2003, 304, (3), 463-470 (Pubitemid 36506518)
17. Kim, J. S.; He, L.; Qian, T.; Lemasters, J. J. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. Curr. Mol. Med., 2003, 3, (6), 527-535 (Pubitemid 37173382)
18. Kinnally, K. W.; Peixoto, P. M.; Ryu, S. Y.; Dejean, L. M. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim. Biophys. Acta, 2010, 1813, (4), 616-622
19. Ricchelli, F.; Sileikyte, J.; Bernardi, P. Shedding light on the mitochondrial permeability transition. Biochim. Biophys. Acta, 2011, 1807, (5), 482-490
20. Baines, C. P.; Kaiser, R. A.; Purcell, N. H.; Blair, N. S.; Osinska, H.; Hambleton, M. A.; Brunskill, E. W.; Sayen, M. R.; Gottlieb, R. A.; Dorn, G. W.; Robbins, J.; Molkentin, J. D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature, 2005, 434, (7033), 658-662 (Pubitemid 40488559)
21. Lemasters, J. J.; Theruvath, T. P.; Zhong, Z.; Nieminen, A. L. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta, 2009, 1787, (11), 1395-1401
22. Kass, G. E.; Price, S. C. Role of mitochondria in drug-induced cholestatic injury. Clin. Liver Dis., 2008, 12, (1), 27-51, vii (Pubitemid 351163140)
23. Conde de la Rosa, L.; Moshage, H.; Nieto, N. [Hepatocyte oxidant stress and alcoholic liver disease]. Rev. Esp. Enferm. Dig., 2008, 100, (3), 156-163 (Pubitemid 351619612)
24. Boelsterli, U. A.; Lim, P. L. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol., 2007, 220, (1), 92-107 (Pubitemid 46427861)
25. Wallace, K. B.; Starkov, A. A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 353-388 (Pubitemid 30340687)
26. Doi, H.; Horie, T. Salicylic acid-induced hepatotoxicity triggered by oxidative stress. Chem. Biol. Interact., 183, (3), 363-368
27. Davison, C. Salicylate metabolism in man. Ann. N. Y. Acad. Sci., 1971, 179, 249-268
28. Schror, K. Aspirin and Reye syndrome: a review of the evidence. Paediatr. Drugs, 2007, 9, (3), 195-204 (Pubitemid 46849139)
29. Doi, H.; Masubuchi, Y.; Narimatsu, S.; Nishigaki, R.; Horie, T. Salicylic acid-induced lipid peroxidation in rat liver microsomes. Res. Commun. Mol. Pathol. Pharmacol., 1998, 100, (3), 265-271 (Pubitemid 28394990)
30. Doi, H.; Iwasaki, H.; Masubuchi, Y.; Nishigaki, R.; Horie, T. Chemiluminescence associated with the oxidative metabolism of salicylic acid in rat liver microsomes. Chem. Biol. Interact., 2002, 140, (2), 109-119 (Pubitemid 34655534)
31. Yoshida, Y.; Wang, S.; Osame, M. Aspirin induces short-chain free fatty acid accumulation in rats. Eur. J. Pharmacol., 1998, 349, (1), 49-52 (Pubitemid 28270655)
32. Deschamps, D.; Fisch, C.; Fromenty, B.; Berson, A.; Degott, C.; Pessayre, D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J. Pharmacol. Exp. Ther., 1991, 259, (2), 894-904
33. Trost, L. C.; Lemasters, J. J. Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for the pathogenesis of Reye's syndrome. Toxicol. Appl. Pharmacol., 1997, 147, (2), 431-441 (Pubitemid 28062760)
34. 2+-dependent ion channels. J. Bioenerg. Biomembr., 42, (2), 151-163
35. Sipos, E. P.; Tamargo, R. J.; Weingart, J. D.; Brem, H. Inhibition of tumor angiogenesis. Ann. N. Y. Acad. Sci., 1994, 732, 263-272
36. Lin, Q.; Katakura, K.; Suzuki, M. Inhibition of mitochondrial and plastid activity of Plasmodium falciparum by minocycline. FEBS Lett., 2002, 515, (1-3), 71-74 (Pubitemid 34273900)
37. Theruvath, T. P.; Zhong, Z.; Pediaditakis, P.; Ramshesh, V. K.; Currin, R. T.; Tikunov, A.; Holmuhamedov, E.; Lemasters, J. J. Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate storage/reperfusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition. Hepatology, 2008, 47, (1), 236-246
38. Kupsch, K.; Hertel, S.; Kreutzmann, P.; Wolf, G.; Wallesch, C. W.; Siemen, D.; Schonfeld, P. Impairment of mitochondrial function by minocycline. FEBS J., 2009, 276, (6), 1729-1738
39. Cuenca-Lopez, M. D.; Karachitos, A.; Massarotto, L.; Oliveira, P. J.; Aguirre, N.; Galindo, M. F.; Kmita, H.; Jordan, J. Minocycline exerts uncoupling and inhibiting effects on mitochondrial respiration through adenine nucleotide translocase inhibition. Pharmacol. Res., 2011
40. Boelsterli, U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol., 2003, 192, (3), 307-322 (Pubitemid 37311346)
41. Pumford, N. R.; Myers, T. G.; Davila, J. C.; Highet, R. J.; Pohl, L. R. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol., 1993, 6, (2), 147-150 (Pubitemid 23086898)
42. Kretz-Rommel, A.; Boelsterli, U. A. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct. Drug Metab. Dispos., 1994, 22, (6), 956-961 (Pubitemid 24377373)
43. Poon, G. K.; Chen, Q.; Teffera, Y.; Ngui, J. S.; Griffin, P. R.; Braun, M. P.; Doss, G. A.; Freeden, C.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W. Bioactivation of diclofenac via benzoquinone imine intermediatesidentification of urinary mercapturic acid derivatives in rats and humans. Drug Metab. Dispos., 2001, 29, (12), 1608-1613 (Pubitemid 33111594)
44. Shen, S.; Marchick, M. R.; Davis, M. R.; Doss, G. A.; Pohl, L. R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol., 1999, 12, (2), 214-222 (Pubitemid 29096071)
45. Masubuchi, Y.; Yamada, S.; Horie, T. Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 2000, 292, (3), 982-987 (Pubitemid 30136591)
46. Masubuchi, Y.; Nakayama, S.; Horie, T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology, 2002, 35, (3), 544-551 (Pubitemid 34183957)
47. Siu, W. P.; Pun, P. B.; Latchoumycandane, C.; Boelsterli, U. A. Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenacinduced hepatocyte injury: Multiple protective roles of cyclosporin A. Toxicol. Appl. Pharmacol., 2008, 227, (3), 451-461
48. Kasuya, F.; Nishizawa, R.; Masuyama, T.; Kazumi, M. Evaluation of a screening method by liquid chromatography-tandem mass spectrometry for estimating effect of drugs on the activation and beta-oxidation of fatty acids in mitochondria. J. Pharm. Pharmacol., 2010, 62, (12), 1697-1703
49. Vad, N. M.; Yount, G.; Moore, D.; Weidanz, J.; Moridani, M. Y. Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J. Pharm. Sci., 2009, 98, (4), 1409-1425
50. Gujral, J. S.; Knight, T. R.; Farhood, A.; Bajt, M. L.; Jaeschke, H. Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? Toxicol. Sci., 2002, 67, (2), 322-328 (Pubitemid 34746486)
51. Hanawa, N.; Shinohara, M.; Saberi, B.; Gaarde, W. A.; Han, D.; Kaplowitz, N. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J. Biol. Chem., 2008, 283, (20), 13565-13577
52. Bradham, C. A.; Stachlewitz, R. F.; Gao, W.; Qian, T.; Jayadev, S.; Jenkins, G.; Hannun, Y.; Lemasters, J. J.; Thurman, R. G.; Brenner, D. A. Reperfusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology, 1997, 25, (5), 1128-1135 (Pubitemid 27199939)
53. Schwabe, R. F. Cell death in the liver-all roads lead to JNK. Gastroeterology, 2006, 131, (1), 314-316 (Pubitemid 44015771)
54. Dahlin, D. C.; Miwa, G. T.; Lu, A. Y.; Nelson, S. D. N-acetyl-p- benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. U. S. A., 1984, 81, (5), 1327-1331 (Pubitemid 14173462)
55. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov., 2005, 4, (6), 489-499 (Pubitemid 40861991)
56. Jollow, D. J.; Mitchell, J. R.; Potter, W. Z.; Davis, D. C.; Gillette, J. R.; Brodie, B. B. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther., 1973, 187, (1), 195-202
57. Pumford, N. R.; Halmes, N. C. Protein targets of xenobiotic reactive intermediates. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 91-117 (Pubitemid 27238871)
58. Sun, K.; Liu, Z. S.; Sun, Q. Role of mitochondria in cell apoptosis during hepatic ischemia-reperfusion injury and protective effect of ischemic postconditioning. World J. Gastroenterol., 2004, 10, (13), 1934-1938 (Pubitemid 39029296)
59. Klouz, A.; Said, D. B.; Ferchichi, H.; Kourda, N.; Ouanes, L.; Lakhal, M.; Tillement, J. P.; Morin, D. Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N'-(2-hydroxy-3, 4-dimethoxybenzyl) - piperazine (BHDP), a sigma1 ligand. Eur. J. Pharmacol., 2008, 578, (2-3), 292-299 (Pubitemid 350309587)
60. Elimadi, A.; Sapena, R.; Settaf, A.; Le Louet, H.; Tillement, J.; Morin, D. Attenuation of liver normothermic ischemia-reperfusion injury by preservation of mitochondrial functions with S-15176, a potent trimetazidine derivative. Biochem. Pharmacol., 2001, 62, (4), 509-516 (Pubitemid 32607734)
61. Detmers, P. A.; Lo, S. K.; Olsen-Egbert, E.; Walz, A.; Baggiolini, M.; Cohn, Z. A. Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J. Exp. Med., 1990, 171, (4), 1155-1162 (Pubitemid 20120139)
62. Scott, I. D.; Nicholls, D. G. Energy transduction in intact synaptosomes. Influence of plasma-membrane depolarization on the respiration and membrane potential of internal mitochondria determined in situ. Biochem. J., 1980, 186, (1), 21-33 (Pubitemid 10152072)
63. Farber, J. L. The role of calcium in lethal cell injury. Chem. Res. Toxicol., 1990, 3, (6), 503-508
64. Kirichok, Y.; Krapivinsky, G.; Clapham, D. E. The mitochondrial calcium uniporter is a highly selective ion channel. Nature, 2004, 427, (6972), 360-364 (Pubitemid 38133664)
65. Nicholls, D.; Akerman, K. Mitochondrial calcium transport. Biochim. Biophys. Acta, 1982, 683, (1), 57-88
66. Nicholls, D. G. Mitochondria and calcium signaling. Cell Calcium, 2005, 38, (3-4), 311-317 (Pubitemid 41283269)
67. Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J., 1999, 341(Pt 2), 233-249 (Pubitemid 29373645)
68. Kroemer, G.; Reed, J. C. Mitochondrial control of cell death. Nat. Med., 2000, 6, (5), 513-519 (Pubitemid 30305900)
69. O'Rourke, B.; Cortassa, S.; Aon, M. A. Mitochondrial ion channels: gatekeepers of life and death. Physiology (Bethesda), 2005, 20, 303-315 (Pubitemid 41457396)
70. Broekemeier, K. M.; Dempsey, M. E.; Pfeiffer, D. R. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J. Biol. Chem., 1989, 264, (14), 7826-7830 (Pubitemid 19137258)
71. Hirakawa, A.; Takeyama, N.; Nakatani, T.; Tanaka, T. Mitochondrial permeability transition and cytochrome c release in ischemia-reperfusion injury of the rat liver. J. Surg. Res., 2003, 111, (2), 240-247 (Pubitemid 36808916)
72. Tarrab, E.; Huet, P. M.; Brault, A.; Rocheleau, B.; Laurens, M.; Crenesse, D. Cyclosporin-A Does Not Prevent Cold Ischemia/Reperfusion Injury of Rat Livers. J. Surg. Res., 2011
73. Morin, D.; Pires, F.; Plin, C.; Tillement, J. P. Role of the permeability transition pore in cytochrome C release from mitochondria during ischemiareperfusion in rat liver. Biochem. Pharmacol., 2004, 68, (10), 2065-2073 (Pubitemid 39346196)
74. Jassem, W.; Fuggle, S. V.; Rela, M.; Koo, D. D.; Heaton, N. D. The role of mitochondria in ischemia/reperfusion injury. Transplantation, 2002, 73, (4), 493-499 (Pubitemid 34193605)
75. Theruvath, T. P.; Snoddy, M. C.; Zhong, Z.; Lemasters, J. J. Mitochondrial permeability transition in liver ischemia and reperfusion: role of c-Jun. N-terminal kinase 2. Transplantation, 2008, 85, (10), 1500-1504
76. Novgorodov, S. A.; Gudz, T. I. Ceramide and mitochondria in ischemia/reperfusion. J. Cardiovasc. Pharmacol., 2009, 53, (3), 198-208
77. Eismann, T.; Huber, N.; Shin, T.; Kuboki, S.; Galloway, E.; Wyder, M.; Edwards, M. J.; Greis, K. D.; Shertzer, H. G.; Fisher, A. B.; Lentsch, A. B. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, (2), G266-274
78. Trauner, M.; Meier, P. J.; Boyer, J. L. Molecular pathogenesis of cholestasis. N. Engl. J. Med., 1998, 339, (17), 1217-1227
79. Pan, P. H.; Lin, S. Y.; Ou, Y. C.; Chen, W. Y.; Chuang, Y. H.; Yen, Y. J.; Liao, S. L.; Raung, S. L.; Chen, C. J. Stearic acid attenuates cholestasis-induced liver injury. Biochem. Biophys. Res. Commun., 391, (3), 1537-1542
80. Lee, S.; Kim, S.; Le, H. D.; Meisel, J.; Strijbosch, R. A.; Nose, V.; Puder, M. Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids. J. Pediatr. Surg., 2008, 43, (11), 2010-2015
81. Reyes-Gordillo, K.; Segovia, J.; Shibayama, M.; Tsutsumi, V.; Vergara, P.; Moreno, M. G.; Muriel, P. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam. Clin. Pharmacol., 2008, 22, (4), 417-427
82. Chen, W. Y.; Chen, C. J.; Liao, J. W.; Mao, F. C. Chromium attenuates hepatic damage in a rat model of chronic cholestasis. Life Sci., 2009, 84, (17-18), 606-614
83. Dold, S.; Laschke, M. W.; Lavasani, S.; Menger, M. D.; Jeppsson, B.; Thorlacius, H. Simvastatin protects against cholestasis-induced liver injury. Br. J. Pharmacol., 2009, 156, (3), 466-474
84. Greim, H.; Trulzsch, D.; Roboz, J.; Dressler, K.; Czygan, P.; Hutterer, F.; Schaffner, F.; Popper, H. Mechanism of cholestasis. 5. Bile acids in normal rat livers and in those after bile duct ligation. Gastroenterology, 1972, 63, (5), 837-845
85. Rolo, A. P.; Oliveira, P. J.; Moreno, A. J.; Palmeira, C. M. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol. Sci., 2000, 57, (1), 177-185
86. Krahenbuhl, S.; Stucki, J.; Reichen, J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology, 1992, 15, (6), 1160-1166
87. Schaffner, F.; Bacchin, P. G.; Hutterer, F.; Scharnbeck, H. H.; Sarkozi, L. L.; Denk, H.; Popper, H. Mechanism of cholestasis. 4. Structural and biochemical changes in the liver and serum in rats after bile duct ligation. Gastroenterology, 1971, 60, (5), 888-897
88. Spivey, J. R.; Bronk, S. F.; Gores, G. J. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of AT P depletion and cytosolic free calcium. J. Clin. Invest., 1993, 92, (1), 17-24 (Pubitemid 23208976)
89. Goldfarb, S.; Singer, E. J.; Popper, H. Experimental cholangitis due to alphanaphthyl-isothiocyanate (ANIT). Am. J. Pathol., 1962, 40, 685-698
90. Plaa, G. L.; Priestly, B. G. Intrahepatic cholestasis induced by drugs and chemicals. Pharmacol. Rev., 1976, 28, (3), 207-273 (Pubitemid 8099930)
91. Rolo, A. P.; Oliveira, P. J.; Seica, R.; Santos, M. S.; Moreno, A. J.; Palmeira, C. M. Improved efficiency of hepatic mitochondrial function in rats with cholestasis induced by an acute dose of alpha-naphthylisothiocyanate. Toxicol. Appl. Pharmacol., 2002, 182, (1), 20-26 (Pubitemid 34775473)
92. Rolo, A. P.; Oliveira, P. J.; Seica, R.; Santos, M. S.; Moreno, A. J.; Palmeira, C. M. Disruption of mitochondrial calcium homeostasis after chronic alphanaphthylisothiocyanate administration: relevance for cholestasis. J. Investig. Med., 2002, 50, (3), 193-200 (Pubitemid 34522661)
93. Palmeira, C. M.; Ferreira, F. M.; Rolo, A. P.; Oliveira, P. J.; Santos, M. S.; Moreno, A. J.; Cipriano, M. A.; Martins, M. I.; Seica, R. Histological changes and impairment of liver mitochondrial bioenergetics after long-term treatment with alpha-naphthyl-isothiocyanate (ANIT). Toxicology, 2003, 190, (3), 185-196 (Pubitemid 36966705)
94. Oliveira, P. J.; Rolo, A. P.; Seica, R.; Santos, M. S.; Palmeira, C. M.; Moreno, A. J. Cardiac mitochondrial calcium loading capacity is severely affected after chronic cholestasis in Wistar rats. J. Investig. Med., 2003, 51, (2), 86-94 (Pubitemid 36307586)
95. Oliveira, P. J.; Rolo, A. P.; Seica, R.; Santos, M. S.; Palmeira, C. M.; Moreno, A. J. Reduction in cardiac mitochondrial calcium loading capacity is observable during alpha-naphthylisothiocyanate-induced acute cholestasis: a clue for hepatic-derived cardiomyopathies? Biochim. Biophys. Acta, 2003, 1637, (1), 39-45 (Pubitemid 36071594)
96. Ferreira, M.; Coxito, P. M.; Sardao, V. A.; Palmeira, C. M.; Oliveira, P. J. Bile acids are toxic for isolated cardiac mitochondria: a possible cause for hepatic-derived cardiomyopathies? Cardiovasc. Toxicol., 2005, 5, (1), 63-73 (Pubitemid 40655444)
97. Hezode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goeser, T.; Bronowicki, J. P.; Bourliere, M.; Gharakhanian, S.; Bengtsson, L.; McNair, L.; George, S.; Kieffer, T.; Kwong, A.; Kauffman, R. S.; Alam, J.; Pawlotsky, J. M.; Zeuzem, S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 2009, 360, (18), 1839-1850
98. Nomura-Takigawa, Y.; Nagano-Fujii, M.; Deng, L.; Kitazawa, S.; Ishido, S.; Sada, K.; Hotta, H. Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. J. Gen. Virol., 2006, 87, (Pt 7), 1935-1945 (Pubitemid 43985876)
99. Campbell, R. V.; Yang, Y.; Wang, T.; Rachamallu, A.; Li, Y.; Watowich, S. J.; Weinman, S. A. Chapter 20 Effects of hepatitis C core protein on mitochondrial electron transport and production of reactive oxygen species. Methods Enzymol., 2009, 456, 363-380
100. Piccoli, C.; Scrima, R.; Quarato, G.; D'Aprile, A.; Ripoli, M.; Lecce, L.; Boffoli, D.; Moradpour, D.; Capitanio, N. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology, 2007, 46, (1), 58-65 (Pubitemid 47171921)
101. Wang, T.; Campbell, R. V.; Yi, M. K.; Lemon, S. M.; Weinman, S. A. Role of Hepatitis C virus core protein in viral-induced mitochondrial dysfunction. J. Viral Hepat., 2009
102. Romanowski, T.; Sikorska, K.; Bielawski, K. P. UGT1A1 gene polymorphism as a potential factor inducing iron overload in the pathogenesis of type 1 hereditary hemochromatosis. Hepatol Res, 2009, 39, (5), 469-478
103. Altes, A.; Bach, V.; Ruiz, A.; Esteve, A.; Remacha, A. F.; Sarda, M. P.; Felez, J.; Baiget, M. Does the SLC40A1 gene modify HFE-related haemochromatosis phenotypes? Ann. Hematol., 2009, 88, (4), 341-345
104. Isom, H. C.; McDevitt, E. I.; Moon, M. S. Elevated hepatic iron: a confounding factor in chronic hepatitis C. Biochim. Biophys. Acta, 2009, 1790, (7), 650-662
105. Levi, S.; Rovida, E. The role of iron in mitochondrial function. Biochim. Biophys. Acta, 2009, 1790, (7), 629-636
106. Arosio, P.; Ingrassia, R.; Cavadini, P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim. Biophys. Acta, 2009, 1790, (7), 589-599
107. Corradini, E.; Ferrara, F.; Pietrangelo, A. Iron and the liver. Pediatr. Endocrinol. Rev., 2004, 2 Suppl 2, 245-248
108. Bacon, B. R.; Park, C. H.; Brittenham, G. M.; O'Neill, R.; Tavill, A. S. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology, 1985, 5, (5), 789-797 (Pubitemid 15236623)
109. Bacon, B. R.; Tavill, A. S.; Brittenham, G. M.; Park, C. H.; Recknagel, R. O. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J. Clin. Invest., 1983, 71, (3), 429-439 (Pubitemid 13160788)
110. Almeida, A. M.; Bertoncini, C. R.; Borecky, J.; Souza-Pinto, N. C.; Vercesi, A. E. Mitochondrial DNA damage associated with lipid peroxidation of the mitochondrial membrane induced by Fe2+-citrate. An Acad Bras Cienc, 2006, 78, (3), 505-514 (Pubitemid 44371941)
111. Hayes, J. D.; McLellan, L. I. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic. Res., 1999, 31, (4), 273-300 (Pubitemid 29452854)
112. Pietrangelo, A.; Montosi, G.; Garuti, C.; Contri, M.; Giovannini, F.; Ceccarelli, D.; Masini, A. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J. Bioenerg. Biomembr., 2002, 34, (1), 67-79 (Pubitemid 34157707)
113. Masini, A.; Ceccarelli, D.; Giovannini, F.; Montosi, G.; Garuti, C.; Pietrangelo, A. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J. Bioenerg. Biomembr., 2000, 32, (2), 175-182 (Pubitemid 30602304)
114. Pietrangelo, A.; Borella, F.; Casalgrandi, G.; Montosi, G.; Ceccarelli, D.; Gallesi, D.; Giovannini, F.; Gasparetto, A.; Masini, A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology, 1995, 109, (6), 1941-1949
115. Pfeiffer, R. F. Wilson's disease. Handb Clin Neurol, 2011, 100, 681-709
116. Wan, L.; Tsai, C. H.; Hsu, C. M.; Huang, C. C.; Yang, C. C.; Liao, C. C.; Wu, C. C.; Hsu, Y. A.; Lee, C. C.; Liu, S. C.; Lin, W. D.; Tsai, F. J. Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B. Hepatology, 2010, 52, (5), 1662-1670
117. Gromadzka, G.; Rudnicka, M.; Chabik, G.; Przybylkowski, A.; Czlonkowska, A. Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilson's disease. J. Hepatol., 2011
118. Mansouri, A.; Gaou, I.; Fromenty, B.; Berson, A.; Letteron, P.; Degott, C.; Erlinger, S.; Pessayre, D. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterolog y, 1997, 113, (2), 599-605 (Pubitemid 27351789)
119. Sternlieb, I. Fraternal concordance of types of abnormal hepatocellular mitochondria in Wilson's disease. Hepatology, 1992, 16, (3), 728-732
120. Roberts, E. A.; Robinson, B. H.; Yang, S. Mitochondrial structure and function in the untreated Jackson toxic milk (tx-j) mouse, a model for Wilson disease. Mol. Genet. Metab., 2008, 93, (1), 54-65 (Pubitemid 350236005)
121. Roy, D. N.; Mandal, S.; Sen, G.; Biswas, T. Superoxide anion mediated mitochondrial dysfunction leads to hepatocyte apoptosis preferentially in the periportal region during copper toxicity in rats. Chem. Biol. Interact., 2009, 182, (2-3), 136-147
122. Sokol, R. J.; Devereaux, M.; Mierau, G. W.; Hambidge, K. M.; Shikes, R. H. Oxidant injury to hepatic mitochondrial lipids in rats with dietary copper overload. Modification by vitamin E deficiency. Gastroenterology, 1990, 99, (4), 1061-1071 (Pubitemid 20338465)
123. Gu, M.; Cooper, J. M.; Butler, P.; Walker, A. P.; Mistry, P. K.; Dooley, J. S.; Schapira, A. H. Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet, 2000, 356, (9228), 469-474 (Pubitemid 30496819)
124. Sheline, C. T.; Choi, D. W. Cu2+ toxicity inhibition of mitochondrial dehydrogenases in vitro and in vivo. Ann. Neurol., 2004, 55, (5), 645-653 (Pubitemid 38544324)
125. Chang, E. S. Ultrastructural morphogenesis of mitochondria in alcoholic liver. Acta Pathol. Jpn., 1987, 37, (2), 213-224
126. Yan, M.; Zhu, P.; Liu, H. M.; Zhang, H. T.; Liu, L. Ethanol induced mitochondria injury and permeability transition pore opening: role of mitochondria in alcoholic liver disease. World J. Gastroenterol., 2007, 13, (16), 2352-2356 (Pubitemid 46860738)
127. Krahenbuhl, S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. Pharmacol. Ther., 1993, 60, (1), 1-38 (Pubitemid 24052880)
128. Spach, P. I.; Bottenus, R. E.; Cunningham, C. C. Control of adenine nucleotide metabolism in hepatic mitochondria from rats with ethanol-induced fatty liver. Biochem. J., 1982, 202, (2), 445-452 (Pubitemid 12103844)
129. Thayer, W. S.; Rubin, E. Effects of chronic ethanol consumption on the respiratory chain of rat liver submitochondrial particles. Adv. Exp. Med. Biol., 1980, 132, 385-392
130. Schilling, R. J.; Reitz, R. C. A mechanism for ethanol-induced damage to liver mitochondrial structure and function. Biochim. Biophys. Acta, 1980, 603, (2), 266-277 (Pubitemid 11165828)
131. Sykora, P.; Kharbanda, K. K.; Crumm, S. E.; Cahill, A. S-adenosyl-L-methionine co-administration prevents the ethanol-elicited dissociation of hepatic mitochondrial ribosomes in male rats. Alcohol. Clin. Exp. Res., 2009, 33, (1), 1-9
132. Pessayre, D.; Mansouri, A.; Haouzi, D.; Fromenty, B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol., 1999, 15, (6), 367-373 (Pubitemid 30233061)
133. Paradis, V.; Bedossa, P. Definition and natural history of metabolic steatosis: histology and cellular aspects. Diabetes Metab., 2008, 34, (6 Pt 2), 638-642
134. Wagenknecht, L. E.; Scherzinger, A. L.; Stamm, E. R.; Hanley, A. J.; Norris, J. M.; Chen, Y. D.; Bryer-Ash, M.; Haffner, S. M.; Rotter, J. I. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring), 2009, 17, (6), 1240-1246
135. Grattagliano, I.; Palmieri, V. O.; Portincasa, P.; Moschetta, A.; Palasciano, G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J. Nutr. Biochem., 2008, 19, (8), 491-504 (Pubitemid 351952322)
136. Matsuzawa, Y. The metabolic syndrome and adipocytokines. FEBS Lett., 2006, 580, (12), 2917-2921 (Pubitemid 43729162)
137. Paschos, P.; Paletas, K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009, 13, (1), 9-19
138. Matteoni, C. A.; Younossi, Z. M.; Gramlich, T.; Boparai, N.; Liu, Y. C.; McCullough, A. J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterolog y, 1999, 116, (6), 1413-1419 (Pubitemid 29258890)
139. Caldwell, S. H.; Oelsner, D. H.; Iezzoni, J. C.; Hespenheide, E. E.; Battle, E. H.; Driscoll, C. J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology, 1999, 29, (3), 664-669 (Pubitemid 29109578)
140. Pessayre, D.; Fromenty, B. NASH: a mitochondrial disease. J. Hepatol., 2005, 42, (6), 928-940 (Pubitemid 40693212)
141. Cortez-Pinto, H.; Chatham, J.; Chacko, V. P.; Arnold, C.; Rashid, A.; Diehl, A. M. Alterations in liver AT P homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA, 1999, 282, (17), 1659-1664 (Pubitemid 29513973)
142. Sanyal, A. J.; Campbell-Sargent, C.; Mirshahi, F.; Rizzo, W. B.; Contos, M. J.; Sterling, R. K.; Luketic, V. A.; Shiffman, M. L.; Clore, J. N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterolog y, 2001, 120, (5), 1183-1192 (Pubitemid 32246672)
143. Haque, M.; Sanyal, A. J. The metabolic abnormalities associated with nonalcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol., 2002, 16, (5), 709-731
144. Perez-Carreras, M.; Del Hoyo, P.; Martin, M. A.; Rubio, J. C.; Martin, A.; Castellano, G.; Colina, F.; Arenas, J.; Solis-Herruzo, J. A. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003, 38, (4), 999-1007 (Pubitemid 37221683)
145. Dalen, K. T.; Ulven, S. M.; Arntsen, B. M.; Solaas, K.; Nebb, H. I. PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. J. Lipid Res., 2006, 47, (5), 931-943 (Pubitemid 43778694)
146. Tilg, H.; Hotamisligil, G. S. Nonalcoholic fatty liver disease: Cytokineadipokine interplay and regulation of insulin resistance. Gastroenterology, 2006, 131, (3), 934-945 (Pubitemid 44307061)
147. Tsochatzis, E.; Papatheodoridis, G. V.; Archimandritis, A. J. The evolving role of leptin and adiponectin in chronic liver diseases. Am. J. Gastroenterol., 2006, 101, (11), 2629-2640 (Pubitemid 44665263)
148. Caldwell, S. H.; Swerdlow, R. H.; Khan, E. M.; Iezzoni, J. C.; Hespenheide, E. E.; Parks, J. K.; Parker, W. D., Jr. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J. Hepatol., 1999, 31, (3), 430-434
149. Petrosillo, G.; Portincasa, P.; Grattagliano, I.; Casanova, G.; Matera, M.; Ruggiero, F. M.; Ferri, D.; Paradies, G. Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochim. Biophys. Acta, 2007, 1767, (10), 1260-1267 (Pubitemid 47498313)
150. Grattagliano, I.; Caraceni, P.; Calamita, G.; Ferri, D.; Gargano, I.; Palasciano, G.; Portincasa, P. Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur. J. Clin. Invest., 2008, 38, (7), 523-530 (Pubitemid 351832034)
151. Kim, J. S.; Qian, T.; Lemasters, J. J. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. Gastroenterology, 2003, 124, (2), 494-503 (Pubitemid 36169265)
152. Dunn, C. J.; Lea, A. P.; Wagstaff, A. J. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs, 1997, 54, (1), 161-185 (Pubitemid 27300048)
153. Che, Q.; Schreiber, M. J., Jr.; Rafey, M. A. Beta-blockers for hypertension: are they going out of style? Cleve. Clin. J. Med., 2009, 76, (9), 533-542
154. Yue, T. L.; Cheng, H. Y.; Lysko, P. G.; McKenna, P. J.; Feuerstein, R.; Gu, J. L.; Lysko, K. A.; Davis, L. L.; Feuerstein, G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther., 1992, 263, (1), 92-98
155. Feuerstein, G. Z.; Ruffolo, R. R., Jr. Carvedilol, a novel vasodilating betablocker with the potential for cardiovascular organ protection. Eur. Heart J., 1996, 17 Suppl B, 24-29 (Pubitemid 26136857)
156. Aruoma, O. I. Scavenging of hypochlorous acid by carvedilol and ebselen in vitro. Gen. Pharmacol., 1997, 28, (2), 269-272 (Pubitemid 27016137)
157. Oettl, K.; Greilberger, J.; Zangger, K.; Haslinger, E.; Reibnegger, G.; Jurgens, G. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem. Pharmacol., 2001, 62, (2), 241-248 (Pubitemid 32522945)
158. Rolo, A. P.; Oliveira, P. J.; Moreno, A. J.; Palmeira, C. M. Protective effect of carvedilol on chenodeoxycholate induction of the permeability transition pore. Biochem. Pharmacol., 2001, 61, (11), 1449-1454 (Pubitemid 32452361)
159. Abreu, R. M.; Santos, D. J.; Moreno, A. J. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J. Pharmacol. Exp. Ther., 2000, 295, (3), 1022-1030
160. Ben Mosbah, I.; Rosello-Catafau, J.; Alfany-Fernandez, I.; Rimola, A.; Parellada, P. P.; Mitjavila, M. T.; Lojek, A.; Ben Abdennebi, H.; Boillot, O.; Rodes, J.; Peralta, C. Addition of carvedilol to University Wisconsin solution improves rat steatotic and nonsteatotic liver preservation. Liver Transpl., 16, (2), 163-171
161. Hagmeyer, K. O.; Stein, J. Hepatotoxicity associated with carvedilol. Ann. Pharmacother., 2001, 35, (11), 1364-1366 (Pubitemid 33042067)
162. Catania, A. S.; de Barros, C. R.; Ferreira, S. R. [Vitamins and minerals with antioxidant properties and cardiometabolic risk: controversies and perspectives]. Arq. Bras. Endocrinol. Metabol., 2009, 53, (5), 550-559
163. Soden, J. S.; Devereaux, M. W.; Haas, J. E.; Gumpricht, E.; Dahl, R.; Gralla, J.; Traber, M. G.; Sokol, R. J. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology, 2007, 46, (2), 485-495 (Pubitemid 47344784)
164. Kaur, J.; Shalini, S.; Bansal, M. P. Influence of vitamin E on alcohol-induced changes in antioxidant defenses in mice liver. Toxicol. Mech. Methods
165. Lonn, E.; Bosch, J.; Yusuf, S.; Sheridan, P.; Pogue, J.; Arnold, J. M.; Ross, C.; Arnold, A.; Sleight, P.; Probstfield, J.; Dagenais, G. R. Effects of longterm vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 2005, 293, (11), 1338-1347 (Pubitemid 40381486)
166. Portincasa, P.; Moschetta, A.; Palasciano, G. Cholesterol gallstone disease. Lancet, 2006, 368, (9531), 230-239 (Pubitemid 44037798)
167. Lazaridis, K. N.; Gores, G. J.; Lindor, K. D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J. Hepatol., 2001, 35, (1), 134-146 (Pubitemid 32646237)
168. Hagey, L. R.; Crombie, D. L.; Espinosa, E.; Carey, M. C.; Igimi, H.; Hofmann, A. F. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J. Lipid Res., 1993, 34, (11), 1911-1917 (Pubitemid 23324966)
169. Copaci, I.; Micu, L.; Iliescu, L.; Voiculescu, M. New therapeutical indications of ursodeoxycholic acid. Rom J Gastroenterol, 2005, 14, (3), 259-266 (Pubitemid 41494480)
170. Sokol, R. J.; McKim, J. M., Jr.; Goff, M. C.; Ruyle, S. Z.; Devereaux, M. W.; Han, D.; Packer, L.; Everson, G. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology, 1998, 114, (1), 164-174 (Pubitemid 28020966)
171. Rolo, A. P.; Palmeira, C. M.; Wallace, K. B. Mitochondrially mediated synergistic cell killing by bile acids. Biochim. Biophys. Acta, 2003, 1637, (1), 127-132 (Pubitemid 36071606)
172. Yerushalmi, B.; Dahl, R.; Devereaux, M. W.; Gumpricht, E.; Sokol, R. J. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology, 2001, 33, (3), 616-626 (Pubitemid 32185224)
173. Serviddio, G.; Pereda, J.; Pallardo, F. V.; Carretero, J.; Borras, C.; Cutrin, J.; Vendemiale, G.; Poli, G.; Vina, J.; Sastre, J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology, 2004, 39, (3), 711-720 (Pubitemid 38337650)
174. Rolo, A. P.; Palmeira, C. M.; Holy, J. M.; Wallace, K. B. Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: the switch between apoptosis and necrosis. Toxicol. Sci., 2004, 79, (1), 196-204 (Pubitemid 38660263)
175. Yi, J. R.; Lu, S.; Fernandez-Checa, J.; Kaplowitz, N. Expression cloning of a rat hepatic reduced glutathione transporter with canalicular characteristics. J. Clin. Invest., 1994, 93, (4), 1841-1845 (Pubitemid 24116428)
176. Jennische, E. Possible influence of glutathione on postischemic liver injury. Acta Pathol Microbiol Immunol Scand A, 1984, 92, (1), 55-64 (Pubitemid 14192899)
177. Cho, W. H.; Kim, D. G.; Murase, N.; Mischinger, H. J.; Todo, S.; Starzl, T. E. Comparison of superoxide dismutase, allopurinol, coenzyme Q10, and glutathione for the prevention of warm ischemic injury. Transplantation, 1990, 50, (2), 353-355 (Pubitemid 20259197)
178. Hahn, R.; Wendel, A.; Flohe, L. The fate of extracellular glutathione in the rat. Biochim. Biophys. Acta, 1978, 539, (3), 324-337 (Pubitemid 8289848)
179. Anderson, M. E.; Powrie, F.; Puri, R. N.; Meister, A. Glutathione monoethyl ester: preparation, uptake by tissues, and conversion to glutathione. Arch. Biochem. Biophys., 1985, 239, (2), 538-548 (Pubitemid 15013769)
180. Grattagliano, I.; Wieland, P.; Schranz, C.; Lauterburg, B. H. Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione. J. Pharmacol. Exp. Ther., 1995, 272, (2), 484-488
181. Grattagliano, I.; Vendemiale, G.; Lauterburg, B. H. Reperfusion injury of the liver: role of mitochondria and protection by glutathione ester. J. Surg. Res., 1999, 86, (1), 2-8 (Pubitemid 29418480)
182. Aruoma, O. I.; Halliwell, B.; Hoey, B. M.; Butler, J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem. J., 1988, 256, (1), 251-255
183. Kelly, G. S. Clinical applications of N-acetylcysteine. Altern. Med. Rev., 1998, 3, (2), 114-127 (Pubitemid 128709607)
184. Menor, C.; Fernandez-Moreno, M. D.; Fueyo, J. A.; Escribano, O.; Olleros, T.; Arriaza, E.; Cara, C.; Lorusso, M.; Di Paola, M.; Roman, I. D.; Guijarro, L. G. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J. Pharmacol. Exp. Ther., 2004, 311, (2), 668-676 (Pubitemid 39391554)
185. Ferenci, P.; Dragosics, B.; Dittrich, H.; Frank, H.; Benda, L.; Lochs, H.; Meryn, S.; Base, W.; Schneider, B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol., 1989, 9, (1), 105-113 (Pubitemid 19181371)
186. Valenzuela, A.; Garrido, A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol. Res., 1994, 27, (2), 105-112 (Pubitemid 24257808)
187. Barzaghi, N.; Crema, F.; Gatti, G.; Pifferi, G.; Perucca, E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur. J. Drug Metab. Pharmacokinet., 1990, 15, (4), 333-338
188. Buzzelli, G.; Moscarella, S.; Giusti, A.; Duchini, A.; Marena, C.; Lampertico, M. A pilot study on the liver protective effect of silybinphosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol, 1993, 31, (9), 456-460 (Pubitemid 23262277)
189. Morazzoni, P.; Montalbetti, A.; Malandrino, S.; Pifferi, G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur. J. Drug Metab. Pharmacokinet., 1993, 18, (3), 289-297 (Pubitemid 24009653)
190. Gallo, D.; Giacomelli, S.; Ferlini, C.; Raspaglio, G.; Apollonio, P.; Prislei, S.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Scambia, G. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur. J. Cancer, 2003, 39, (16), 2403-2410 (Pubitemid 37214866)
191. Haddad, Y.; Vallerand, D.; Brault, A.; Haddad, P. S. Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis. Evid. Based Complement. Alternat. Med., 2009
192. Serviddio, G.; Bellanti, F.; Giudetti, A. M.; Gnoni, G. V.; Petrella, A.; Tamborra, R.; Romano, A. D.; Rollo, T.; Vendemiale, G.; Altomare, E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther., 2009, 332, (3), 922-932
193. Bentinger, M.; Tekle, M.; Dallner, G. Coenzyme Q-biosynthesis and functions. Biochem. Biophys. Res. Commun., 396, (1), 74-79
194. Papucci, L.; Schiavone, N.; Witort, E.; Donnini, M.; Lapucci, A.; Tempestini, A.; Formigli, L.; Zecchi-Orlandini, S.; Orlandini, G.; Carella, G.; Brancato, R.; Capaccioli, S. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem., 2003, 278, (30), 28220-28228 (Pubitemid 36900022)
195. Gonzalez, R.; Ferrin, G.; Hidalgo, A. B.; Ranchal, I.; Lopez-Cillero, P.; Santos-Gonzalez, M.; Lopez-Lluch, G.; Briceno, J.; Gomez, M. A.; Poyato, A.; Villalba, J. M.; Navas, P.; de la Mata, M.; Muntane, J. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem. Biol. Interact., 2009, 181, (1), 95-106
196. Tauskela, J. S. MitoQ-a mitochondria-targeted antioxidant. IDrugs, 2007, 10, (6), 399-412
197. Ross, M. F.; Prime, T. A.; Abakumova, I.; James, A. M.; Porteous, C. M.; Smith, R. A.; Murphy, M. P. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem. J., 2008, 411, (3), 633-645 (Pubitemid 351600748)
198. Rodriguez-Cuenca, S.; Cocheme, H. M.; Logan, A.; Abakumova, I.; Prime, T. A.; Rose, C.; Vidal-Puig, A.; Smith, A. C.; Rubinsztein, D. C.; Fearnley, I. M.; Jones, B. A.; Pope, S.; Heales, S. J.; Lam, B. Y.; Neogi, S. G.; McFarlane, I.; James, A. M.; Smith, R. A.; Murphy, M. P. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic. Biol. Med., 2009, 48, (1), 161-172
199. Smith, R. A.; Murphy, M. P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N. Y. Acad. Sci., 2010, 1201, 96-103
200. Gane, E. J.; Weilert, F.; Orr, D. W.; Keogh, G. F.; Gibson, M.; Lockhart, M. M.; Frampton, C. M.; Taylor, K. M.; Smith, R. A.; Murphy, M. P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int., 2010, 30, (7), 1019-1026
201. Chacko, B. K.; Srivastava, A.; Johnson, M.; Benavides, G. A.; Chang, M. J.; Ye, Y.; Jhala, N.; Murphy, M. P.; Kalyanaraman, B.; Usmar, V. D. The mitochondria-targeted ubiquinone MitoQ decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology, 2011
202. Lowes, D. A.; Thottakam, B. M.; Webster, N. R.; Murphy, M. P.; Galley, H. F. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic. Biol. Med., 2008, 45, (11), 1559-1565
203. Whiteman, M.; Spencer, J. P.; Szeto, H. H.; Armstrong, J. S. Do mitochondriotropic antioxidants prevent chlorinative stress-induced mitochondrial and cellular injury? Antioxid. Redox. Signal., 2008, 10, (3), 641-650
204. Haefeli, R. H.; Erb, M.; Gemperli, A. C.; Robay, D.; Courdier Fruh, I.; Anklin, C.; Dallmann, R.; Gueven, N. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS ONE, 2011, 6, (3), e17963
205. Buyse, G. M.; Goemans, N.; van den Hauwe, M.; Thijs, D.; de Groot, I. J.; Schara, U.; Ceulemans, B.; Meier, T.; Mertens, L. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul. Disord., 2011, 21, (6), 396-405
206. Fetoni, A. R.; Ferraresi, A.; Greca, C. L.; Rizzo, D.; Sergi, B.; Tringali, G.; Piacentini, R.; Troiani, D. Antioxidant protection against acoustic trauma by coadministration of idebenone and vitamin E. Neuroreport, 2008, 19, (3), 277-281 (Pubitemid 351322962)
207. Wieland, E.; Oellerich, M.; Braun, F.; Schtuz, E. c-fos and c-jun mRNA expression in a pig liver model of ischemia/reperfusion: effect of extended cold storage and the antioxidant idebenone. Clin. Biochem., 2000, 33, (4), 285-290 (Pubitemid 30670180)
208. Shivaram, K. N.; Winklhofer-Roob, B. M.; Straka, M. S.; Devereaux, M. W.; Everson, G.; Mierau, G. W.; Sokol, R. J. The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria. Free Radic. Biol. Med., 1998, 25, (4-5), 480-492 (Pubitemid 28390303)
209. Bakeeva, L. E.; Barskov, I. V.; Egorov, M. V.; Isaev, N. K.; Kapelko, V. I.; Kazachenko, A. V.; Kirpatovsky, V. I.; Kozlovsky, S. V.; Lakomkin, V. L.; Levina, S. B.; Pisarenko, O. I.; Plotnikov, E. Y.; Saprunova, V. B.; Serebryakova, L. I.; Skulachev, M. V.; Stelmashook, E. V.; Studneva, I. M.; Tskitishvili, O. V.; Vasilyeva, A. K.; Victorov, I. V.; Zorov, D. B.; Skulachev, V. P. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS-and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (Mosc.), 2008, 73, (12), 1288-1299
210. Skulachev, M. V.; Antonenko, Y. N.; Anisimov, V. N.; Chernyak, B. V.; Cherepanov, D. A.; Chistyakov, V. A.; Egorov, M. V.; Kolosova, N. G.; Korshunova, G. A.; Lyamzaev, K. G.; Plotnikov, E. Y.; Roginsky, V. A.; Severina, II; Severin, F. F.; Shkurat, T. P.; Tashlitsky, V. N.; Shidlovsky, K. M.; Vyssokikh, M. Y.; Zamyatnin, A. A., Jr.; Zorov, D. B.; Skulachev, V. P. Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies. Curr. Drug Ta rgets, 2011
211. Lyamzaev, K. G.; Pustovidko, A. V.; Simonyan, R. A.; Rokitskaya, T. I.; Domnina, L. V.; Ivanova, O. Y.; Severina, I. I.; Sumbatyan, N. V.; Korshunova, G. A.; Tashlitsky, V. N.; Roginsky, V. A.; Antonenko, Y. N.; Skulachev, M. V.; Chernyak, B. V.; Skulachev, V. P. Novel Mitochondria-Targeted Antioxidants: Plastoquinone Conjugated with Cationic Plant Alkaloids Berberine and Palmatine. Pharm. Res., 2011
212. Szeto, H. H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J., 2006, 8, (2), E277-283
213. Zhao, K.; Zhao, G. M.; Wu, D.; Soong, Y.; Birk, A. V.; Schiller, P. W.; Szeto, H. H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem., 2004, 279, (33), 34682-34690 (Pubitemid 39318098)
214. Szeto, H. H. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann. N. Y. Acad. Sci., 2008, 1147, 112-121
215. Petri, S.; Kiaei, M.; Damiano, M.; Hiller, A.; Wille, E.; Manfredi, G.; Calingasan, N. Y.; Szeto, H. H.; Beal, M. F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2006, 98, (4), 1141-1148 (Pubitemid 44127789)
216. Pechanova, O.; Simko, F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J. Hypertens. Suppl., 2009, 27, (6), S32-36
217. Bernhard, D.; Wang, X. L. Smoking, oxidative stress and cardiovascular diseases-do anti-oxidative therapies fail? Curr. Med. Chem., 2007, 14, (16), 1703-1712 (Pubitemid 47163408)
218. Warnholtz, A.; Munzel, T. Why do antioxidants fail to provide clinical benefit? Curr Control Trials Cardiovasc Med, 2000, 1, (1), 38-40 (Pubitemid 32219875)
219. Cunha, F. M.; Caldeira da Silva, C. C.; Cerqueira, F. M.; Kowaltowski, A. J. Mild mitochondrial uncoupling as a therapeutic strategy. Curr. Drug Targets, 2011, 12, (6), 783-789